<DOC>
	<DOCNO>NCT01578785</DOCNO>
	<brief_summary>This study investigate efficacy , safety tolerability new formulation glatiramer acetate administer 20 mg/0.5 ml daily versus placebo patient Relapsing-Remitting Multiple Sclerosis ( RRMS ) .</brief_summary>
	<brief_title>An Efficacy , Safety Tolerability Study Glatiramer Acetate ( GA ) 20 mg/0.5 ml New Formulation Administered Daily Subcutaneous ( SC ) Injection Subjects With Relapsing-Remitting Multiple Sclerosis ( RRMS )</brief_title>
	<detailed_description>Approximately 1400 participant plan study , however 178 enrol prior early termination .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>Subjects must meet inclusion criterion order eligible study : Subjects must confirm documented multiple sclerosis ( MS ) diagnosis define 2010 Revised McDonald criterion [ Ann Neurol 2011 : 69:292302 ] , relapsingremitting disease course . Subjects must ambulatory Kurtzke 's Expanded Disability Status Scale ( EDSS ) score 05.5 screen baseline visit . Subjects must relapsefree , stable neurological condition free corticosteroid treatment [ intravenous ( IV ) , intramuscular ( IM ) and/or mouth ( PO ) ] ACTH ( adrenocorticotropic hormone ) 30 day prior screen ( Month1 ) screen baseline ( Month 0 ) visit . Subjects must experience one following : At least one document relapse 12 month prior screen , At least two documented relapse 24 month prior screen , One document relapse 12 24 month prior screen least one document T1Gd enhance lesion magnetic resonance imaging ( MRI ) perform within 12 month prior screen . Subjects must 18 55 year age , inclusive . Women childbearing potential must practice acceptable method birth control [ acceptable method birth control study include : surgical sterilization , intrauterine device , oral contraceptive , contraceptive patch , longacting injectable contraceptive , partner 's vasectomy doublebarrier method ( condom diaphragm spermicide ) ] . Subjects must able sign date write informed consent prior enter study . Subjects must willing able comply protocol requirement duration study . Any following condition exclude subject enter study : Subjects progressive form MS. Use experimental investigational drug , and/or participation drug clinical study within 6 month prior screen . Use immunosuppressive agent ( include Mitoxantrone Fingolimod ) cytotoxic agent within 6 month prior screen visit . Use natalizumab ( Tysabri® ) monoclonal antibody within 2 year prior screen . Use cladribine within 2 year prior screen . Previous treatment immunomodulators [ include IFNβ 1a 1b , IV Immunoglobulin ( IVIg ) ] within 2 month prior screen . Previous use glatiramer acetate ( GA ) glatiramoid . Chronic ( 30 consecutive day ) systemic ( IV , PO IM ) corticosteroid treatment within 6 month prior screen visit . Previous total body irradiation total lymphoid irradiation . Previous stemcell treatment , autologous bone marrow transplantation allogenic bone marrow transplantation . Pregnancy breastfeed . Subjects clinically significant unstable medical surgical condition would preclude safe complete study participation , determine medical history , physical exam , ECG , abnormal laboratory test chest Xray . Such condition may include hepatic , renal metabolic disease , systemic disease , acute infection , current malignancy recent history ( 5 year ) malignancy , major psychiatric disorder , history drug and/or alcohol abuse allergy could detrimental accord investigator 's judgment . A known history sensitivity Gadolinium . Glomerular filtration rate ( GFR ) ≤ 60 mL/minute screen visit Inability successfully undergo MRI scanning . A known drug hypersensitivity Mannitol . Subjects underwent endovascular treatment chronic cerebrospinal venous insufficiency ( CCSVI ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>